BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only -

- FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 -

Read more at prnewswire.com